{"id":180,"date":"2022-11-19T01:24:55","date_gmt":"2022-11-19T01:24:55","guid":{"rendered":"https:\/\/bioventrix.com\/?page_id=180"},"modified":"2023-04-16T20:42:31","modified_gmt":"2023-04-16T20:42:31","slug":"press-releases","status":"publish","type":"page","link":"https:\/\/bioventrix.com\/press-releases\/","title":{"rendered":"Press Releases"},"content":{"rendered":"<p><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-background-position:left center;--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-padding-top:40px;--awb-padding-bottom:40px;--awb-background-color:var(--awb-color4);--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column fusion-flex-align-self-center fusion-animated\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:1.92%;--awb-width-medium:60%;--awb-order-medium:0;--awb-spacing-right-medium:3.2%;--awb-spacing-left-medium:3.2%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\" data-animationType=\"fadeInDown\" data-animationDuration=\"1.0\" data-animationOffset=\"top-into-view\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-title title fusion-title-1 fusion-sep-none fusion-title-text fusion-title-size-one\" style=\"--awb-text-color:var(--awb-color1);--awb-margin-bottom:0px;\"><h1 class=\"fusion-title-heading title-heading-left\" style=\"font-family:&quot;Lato&quot;;font-style:normal;font-weight:400;margin:0;\">Press Releases<\/h1><\/div><\/div><\/div><\/div><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-2 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-padding-top:80px;--awb-padding-bottom:80px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_1_1 1_1 fusion-flex-column fusion-flex-align-self-center\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-blog-shortcode fusion-blog-shortcode-1 fusion-blog-archive fusion-blog-layout-grid-wrapper fusion-blog-pagination fusion-blog-no-images\" style=\"--awb-title-font-size:27px;--awb-title-font-family:&quot;Lato&quot;;--awb-title-font-style:normal;--awb-title-font-weight:400;--grid_separator_color:rgba(54,56,57,0.2);\"><style type=\"text\/css\">.fusion-blog-shortcode-1 .fusion-blog-layout-grid .fusion-post-grid{padding:20px;}.fusion-blog-shortcode-1 .fusion-posts-container{margin-left: -20px !important; margin-right:-20px !important;}<\/style><div class=\"fusion-posts-container fusion-posts-container-pagination fusion-blog-layout-grid fusion-blog-layout-grid-1 isotope\" data-pages=\"3\" data-grid-col-space=\"40\" style=\"margin: -20px -20px 0;min-height:500px;\"><article id=\"blog-1-post-853\" class=\"fusion-post-grid post-853 post type-post status-publish format-standard hentry category-uncategorized\">\n<div class=\"fusion-post-wrapper\" style=\"background-color:var(--awb-color2);border:1px solid var(--awb-color8);border-bottom-width:3px;\"><div class=\"fusion-post-content-wrapper\" style=\"padding:30px 25px 25px 25px;\"><div class=\"fusion-post-content post-content\"><h2 class=\"blog-shortcode-post-title entry-title\"><a href=\"https:\/\/bioventrix.com\/2023\/04\/13\/bioventrix-closes-48-5-million-series-a-financing\/\">BioVentrix<sup>\u00ae<\/sup> Closes $48.5 Million Series A Financing<\/a><\/h2><p class=\"fusion-single-line-meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/bioventrix.com\/author\/merle-adelmanadelmanassociates-com\/\" title=\"Posts by Merle Adelman\" rel=\"author\">Merle Adelman<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2023-05-26T19:06:06+00:00<\/span><span>April 13, 2023<\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><div class=\"fusion-content-sep sep-single sep-solid\"><\/div><div class=\"fusion-post-content-container\"><p>Financing led by Andera Partners including Cormorant Asset Management, Taglich Brothers Inc., Squarepoint Capital, and Richmond Brothers to Support Premarket Approval of Revivent TC\u00ae System for Patients with Ischemic Heart Failure MANSFIELD, MA \u2013 April 13, 2023 \u2013 BioVentrix, Inc., a privately held medical device company developing minimally invasive therapies [...]<\/p><\/div><\/div><div class=\"fusion-meta-info\"><div class=\"fusion-alignleft\"><a class=\"fusion-read-more\" href=\"https:\/\/bioventrix.com\/2023\/04\/13\/bioventrix-closes-48-5-million-series-a-financing\/\" aria-label=\"More on BioVentrix&lt;sup&gt;\u00ae&lt;\/sup&gt; Closes $48.5 Million Series A Financing\">Read More<\/a><\/div><\/div><\/div><div class=\"fusion-clearfix\"><\/div><\/div>\n<\/article>\n<article id=\"blog-1-post-851\" class=\"fusion-post-grid post-851 post type-post status-publish format-standard hentry category-uncategorized\">\n<div class=\"fusion-post-wrapper\" style=\"background-color:var(--awb-color2);border:1px solid var(--awb-color8);border-bottom-width:3px;\"><div class=\"fusion-post-content-wrapper\" style=\"padding:30px 25px 25px 25px;\"><div class=\"fusion-post-content post-content\"><h2 class=\"blog-shortcode-post-title entry-title\"><a href=\"https:\/\/bioventrix.com\/2023\/03\/15\/new-study-demonstrates-accurate-measurement-of-left-ventricular-function-following-treatment-with-bioventrix-revivent-tc-therapy\/\">New Study Demonstrates Accurate Measurement of Left Ventricular Function Following Treatment with BioVentrix Revivent TC<sup>\u00ae<\/sup> Therapy<\/a><\/h2><p class=\"fusion-single-line-meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/bioventrix.com\/author\/merle-adelmanadelmanassociates-com\/\" title=\"Posts by Merle Adelman\" rel=\"author\">Merle Adelman<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2023-05-26T19:07:41+00:00<\/span><span>March 15, 2023<\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><div class=\"fusion-content-sep sep-single sep-solid\"><\/div><div class=\"fusion-post-content-container\"><p>Inward Displacement Approach Assesses HFrEF Patients for Left Ventricular Device Therapy MANSFIELD, MA, USA \u2013 March 15, 2023 \u2013 BioVentrix\u00ae, Inc., a privately held medical device company developing less invasive therapies to directly treat the dilated left ventricle leading to progressive heart failure, today announced the publication of a peer-reviewed [...]<\/p><\/div><\/div><div class=\"fusion-meta-info\"><div class=\"fusion-alignleft\"><a class=\"fusion-read-more\" href=\"https:\/\/bioventrix.com\/2023\/03\/15\/new-study-demonstrates-accurate-measurement-of-left-ventricular-function-following-treatment-with-bioventrix-revivent-tc-therapy\/\" aria-label=\"More on New Study Demonstrates Accurate Measurement of Left Ventricular Function Following Treatment with BioVentrix Revivent TC&lt;sup&gt;\u00ae&lt;\/sup&gt; Therapy\">Read More<\/a><\/div><\/div><\/div><div class=\"fusion-clearfix\"><\/div><\/div>\n<\/article>\n<article id=\"blog-1-post-849\" class=\"fusion-post-grid post-849 post type-post status-publish format-standard hentry category-uncategorized\">\n<div class=\"fusion-post-wrapper\" style=\"background-color:var(--awb-color2);border:1px solid var(--awb-color8);border-bottom-width:3px;\"><div class=\"fusion-post-content-wrapper\" style=\"padding:30px 25px 25px 25px;\"><div class=\"fusion-post-content post-content\"><h2 class=\"blog-shortcode-post-title entry-title\"><a href=\"https:\/\/bioventrix.com\/2023\/02\/08\/bioventrix-names-dr-ori-ben-yehuda-as-chief-medical-officer\/\">BioVentrix Names Dr. Ori Ben-Yehuda as Chief Medical Officer<\/a><\/h2><p class=\"fusion-single-line-meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/bioventrix.com\/author\/merle-adelmanadelmanassociates-com\/\" title=\"Posts by Merle Adelman\" rel=\"author\">Merle Adelman<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2023-05-26T19:08:32+00:00<\/span><span>February 8, 2023<\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><div class=\"fusion-content-sep sep-single sep-solid\"><\/div><div class=\"fusion-post-content-container\"><p>Brings Extensive Clinical Trial and Patient Care Experience to Senior Management Team SAN RAMON, Calif. \u2013 February 08, 2023 \u2013 BioVentrix, Inc., a privately held medical device company focused on the development of less invasive therapies to directly treat the dilated left ventricle and reverse the left ventricular remodeling process [...]<\/p><\/div><\/div><div class=\"fusion-meta-info\"><div class=\"fusion-alignleft\"><a class=\"fusion-read-more\" href=\"https:\/\/bioventrix.com\/2023\/02\/08\/bioventrix-names-dr-ori-ben-yehuda-as-chief-medical-officer\/\" aria-label=\"More on BioVentrix Names Dr. Ori Ben-Yehuda as Chief Medical Officer\">Read More<\/a><\/div><\/div><\/div><div class=\"fusion-clearfix\"><\/div><\/div>\n<\/article>\n<article id=\"blog-1-post-847\" class=\"fusion-post-grid post-847 post type-post status-publish format-standard hentry category-uncategorized\">\n<div class=\"fusion-post-wrapper\" style=\"background-color:var(--awb-color2);border:1px solid var(--awb-color8);border-bottom-width:3px;\"><div class=\"fusion-post-content-wrapper\" style=\"padding:30px 25px 25px 25px;\"><div class=\"fusion-post-content post-content\"><h2 class=\"blog-shortcode-post-title entry-title\"><a href=\"https:\/\/bioventrix.com\/2023\/01\/24\/fda-agrees-to-expanded-access-program-for-the-bioventrix-revivent-tc-system-for-the-treatment-of-ischemic-heart-failure\/\">FDA Agrees to Expanded Access Program for the BioVentrix Revivent TC<sup>\u00ae<\/sup> System for the Treatment of Ischemic Heart Failure<\/a><\/h2><p class=\"fusion-single-line-meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/bioventrix.com\/author\/merle-adelmanadelmanassociates-com\/\" title=\"Posts by Merle Adelman\" rel=\"author\">Merle Adelman<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2023-05-26T19:09:36+00:00<\/span><span>January 24, 2023<\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><div class=\"fusion-content-sep sep-single sep-solid\"><\/div><div class=\"fusion-post-content-container\"><p>Treatment IDE Will Provide Opportunity to Treat Additional Patients in the US SAN RAMON, Calif. \u2013 January 24, 2023 \u2013 BioVentrix, Inc., a privately held medical device company focused on the development of less invasive therapies to directly treat the dilated left ventricle and reverse the left ventricular remodeling process [...]<\/p><\/div><\/div><div class=\"fusion-meta-info\"><div class=\"fusion-alignleft\"><a class=\"fusion-read-more\" href=\"https:\/\/bioventrix.com\/2023\/01\/24\/fda-agrees-to-expanded-access-program-for-the-bioventrix-revivent-tc-system-for-the-treatment-of-ischemic-heart-failure\/\" aria-label=\"More on FDA Agrees to Expanded Access Program for the BioVentrix Revivent TC&lt;sup&gt;\u00ae&lt;\/sup&gt; System for the Treatment of Ischemic Heart Failure\">Read More<\/a><\/div><\/div><\/div><div class=\"fusion-clearfix\"><\/div><\/div>\n<\/article>\n<article id=\"blog-1-post-4\" class=\"fusion-post-grid post-4 post type-post status-publish format-standard hentry category-uncategorized\">\n<div class=\"fusion-post-wrapper\" style=\"background-color:var(--awb-color2);border:1px solid var(--awb-color8);border-bottom-width:3px;\"><div class=\"fusion-post-content-wrapper\" style=\"padding:30px 25px 25px 25px;\"><div class=\"fusion-post-content post-content\"><h2 class=\"blog-shortcode-post-title entry-title\"><a href=\"https:\/\/bioventrix.com\/2022\/01\/27\/bioventrix-expands-heart-failure-treatment-portfolio-with-acquisition-of-materacor-inc\/\">BioVentrix Expands Heart Failure Treatment Portfolio with Acquisition of MateraCor, Inc.<\/a><\/h2><p class=\"fusion-single-line-meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/bioventrix.com\/author\/michael\/\" title=\"Posts by Michael\" rel=\"author\">Michael<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2023-05-26T19:03:20+00:00<\/span><span>January 27, 2022<\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><div class=\"fusion-content-sep sep-single sep-solid\"><\/div><div class=\"fusion-post-content-container\"><p>Revolutionary Heart Failure Therapy Company Also Adds New Executive and Well-Known Board Member to Enhance Expertise   SAN RAMON, Calif. \u2013 January 27, 2022 - BioVentrix, Inc., a privately held medical device company focused on less invasive therapies to treat the left ventricle (LV), known to be the root [...]<\/p><\/div><\/div><div class=\"fusion-meta-info\"><div class=\"fusion-alignleft\"><a class=\"fusion-read-more\" href=\"https:\/\/bioventrix.com\/2022\/01\/27\/bioventrix-expands-heart-failure-treatment-portfolio-with-acquisition-of-materacor-inc\/\" aria-label=\"More on BioVentrix Expands Heart Failure Treatment Portfolio with Acquisition of MateraCor, Inc.\">Read More<\/a><\/div><\/div><\/div><div class=\"fusion-clearfix\"><\/div><\/div>\n<\/article>\n<article id=\"blog-1-post-156\" class=\"fusion-post-grid post-156 post type-post status-publish format-standard hentry category-uncategorized\">\n<div class=\"fusion-post-wrapper\" style=\"background-color:var(--awb-color2);border:1px solid var(--awb-color8);border-bottom-width:3px;\"><div class=\"fusion-post-content-wrapper\" style=\"padding:30px 25px 25px 25px;\"><div class=\"fusion-post-content post-content\"><h2 class=\"blog-shortcode-post-title entry-title\"><a href=\"https:\/\/bioventrix.com\/2021\/07\/21\/bioventrix-announces-raymond-w-cohen-as-chairman-of-the-board-and-newly-appointed-accredited-public-company-directors-rinda-k-sama-and-andrew-g-hinson-to-its-board-of-directors\/\">BioVentrix Announces Raymond W. Cohen as Chairman of the Board and Newly Appointed Accredited Public Company Directors, Rinda K. Sama and Andrew G. Hinson to its Board of Directors<\/a><\/h2><p class=\"fusion-single-line-meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/bioventrix.com\/author\/michael\/\" title=\"Posts by Michael\" rel=\"author\">Michael<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2022-11-18T20:33:34+00:00<\/span><span>July 21, 2021<\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><div class=\"fusion-content-sep sep-single sep-solid\"><\/div><div class=\"fusion-post-content-container\"><p>SAN RAMON, Calif. \u2013 July 21, 2021 \u2013 BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure via Transcatheter Ventricular Restoration (TCVR), today announced the appointment of Raymond W. Cohen as the Company\u2019s chairman and named Rinda K. Sama and Andrew G. Hinson to its [...]<\/p><\/div><\/div><div class=\"fusion-meta-info\"><div class=\"fusion-alignleft\"><a class=\"fusion-read-more\" href=\"https:\/\/bioventrix.com\/2021\/07\/21\/bioventrix-announces-raymond-w-cohen-as-chairman-of-the-board-and-newly-appointed-accredited-public-company-directors-rinda-k-sama-and-andrew-g-hinson-to-its-board-of-directors\/\" aria-label=\"More on BioVentrix Announces Raymond W. Cohen as Chairman of the Board and Newly Appointed Accredited Public Company Directors, Rinda K. Sama and Andrew G. Hinson to its Board of Directors\">Read More<\/a><\/div><\/div><\/div><div class=\"fusion-clearfix\"><\/div><\/div>\n<\/article>\n<article id=\"blog-1-post-159\" class=\"fusion-post-grid post-159 post type-post status-publish format-standard hentry category-uncategorized\">\n<div class=\"fusion-post-wrapper\" style=\"background-color:var(--awb-color2);border:1px solid var(--awb-color8);border-bottom-width:3px;\"><div class=\"fusion-post-content-wrapper\" style=\"padding:30px 25px 25px 25px;\"><div class=\"fusion-post-content post-content\"><h2 class=\"blog-shortcode-post-title entry-title\"><a href=\"https:\/\/bioventrix.com\/2021\/04\/29\/bioventrix-names-jim-dillon-president-and-ceo\/\">BioVentrix Names Jim Dillon President and CEO<\/a><\/h2><p class=\"fusion-single-line-meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/bioventrix.com\/author\/michael\/\" title=\"Posts by Michael\" rel=\"author\">Michael<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2022-11-18T20:36:22+00:00<\/span><span>April 29, 2021<\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><div class=\"fusion-content-sep sep-single sep-solid\"><\/div><div class=\"fusion-post-content-container\"><p>Proven Leader Will Take Revolutionary Heart Failure Therapy Company to Next LevelSAN RAMON, Calif. - April 29, 2021. BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter-based Ventricular Restoration (TCVR), today announced that Jim Dillon has been named President and CEO.In his [...]<\/p><\/div><\/div><div class=\"fusion-meta-info\"><div class=\"fusion-alignleft\"><a class=\"fusion-read-more\" href=\"https:\/\/bioventrix.com\/2021\/04\/29\/bioventrix-names-jim-dillon-president-and-ceo\/\" aria-label=\"More on BioVentrix Names Jim Dillon President and CEO\">Read More<\/a><\/div><\/div><\/div><div class=\"fusion-clearfix\"><\/div><\/div>\n<\/article>\n<article id=\"blog-1-post-774\" class=\"fusion-post-grid post-774 post type-post status-publish format-standard hentry category-uncategorized\">\n<div class=\"fusion-post-wrapper\" style=\"background-color:var(--awb-color2);border:1px solid var(--awb-color8);border-bottom-width:3px;\"><div class=\"fusion-post-content-wrapper\" style=\"padding:30px 25px 25px 25px;\"><div class=\"fusion-post-content post-content\"><h2 class=\"blog-shortcode-post-title entry-title\"><a href=\"https:\/\/bioventrix.com\/2021\/02\/19\/kardio-tech-firma-aus-kalifornien-grundet-deutschland-niederlassung-und-macht-so-innovative-herztherapie-breiter-verfugbar\/\">Kardio-Tech-Firma aus Kalifornien gr\u00fcndet Deutschland-Niederlassung und macht so innovative Herztherapie breiter verf\u00fcgbar<\/a><\/h2><p class=\"fusion-single-line-meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/bioventrix.com\/author\/michael\/\" title=\"Posts by Michael\" rel=\"author\">Michael<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2022-11-26T05:43:35+00:00<\/span><span>February 19, 2021<\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><div class=\"fusion-content-sep sep-single sep-solid\"><\/div><div class=\"fusion-post-content-container\"><p>San Ramon, Kalifornien, und Hilden bei D\u00fcsseldorf, 19. Februar 2021\u201eBringing innovation in cardiology from California to Germany.\u201c So k\u00f6nnte die \u00dcberschrift einer der j\u00fcngsten Firmengr\u00fcndungen in der Medizintechnik-Branche in Deutschland lauten. BioVentrix Inc. ist ein in Privatbesitzt befindliches Unternehmen mit Hauptsitz im kalifornischen San Ramon (USA). Die Firma wurde 2007 [...]<\/p><\/div><\/div><div class=\"fusion-meta-info\"><div class=\"fusion-alignleft\"><a class=\"fusion-read-more\" href=\"https:\/\/bioventrix.com\/2021\/02\/19\/kardio-tech-firma-aus-kalifornien-grundet-deutschland-niederlassung-und-macht-so-innovative-herztherapie-breiter-verfugbar\/\" aria-label=\"More on Kardio-Tech-Firma aus Kalifornien gr\u00fcndet Deutschland-Niederlassung und macht so innovative Herztherapie breiter verf\u00fcgbar\">Read More<\/a><\/div><\/div><\/div><div class=\"fusion-clearfix\"><\/div><\/div>\n<\/article>\n<article id=\"blog-1-post-162\" class=\"fusion-post-grid post-162 post type-post status-publish format-standard hentry category-uncategorized\">\n<div class=\"fusion-post-wrapper\" style=\"background-color:var(--awb-color2);border:1px solid var(--awb-color8);border-bottom-width:3px;\"><div class=\"fusion-post-content-wrapper\" style=\"padding:30px 25px 25px 25px;\"><div class=\"fusion-post-content post-content\"><h2 class=\"blog-shortcode-post-title entry-title\"><a href=\"https:\/\/bioventrix.com\/2021\/02\/08\/bioventrix-receives-2021-nub-status-1-reimbursement-renewal-in-germany-for-the-revivent-tc-transcatheter-ventricular-enhancement-system\/\">BioVentrix Receives 2021 NUB Status 1 Reimbursement Renewal in Germany for the Revivent TC\u2122 TransCatheter Ventricular Enhancement System<\/a><\/h2><p class=\"fusion-single-line-meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/bioventrix.com\/author\/michael\/\" title=\"Posts by Michael\" rel=\"author\">Michael<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2022-11-18T20:39:55+00:00<\/span><span>February 8, 2021<\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><div class=\"fusion-content-sep sep-single sep-solid\"><\/div><div class=\"fusion-post-content-container\"><p>SAN RAMON, Calif. \u2013 February 8, 2021 - BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter based Ventricular Restoration (TCVR), today announced that the German Institute for Hospital Remuneration (InEK) has renewed the NUB Status 1 reimbursement designation in Germany for [...]<\/p><\/div><\/div><div class=\"fusion-meta-info\"><div class=\"fusion-alignleft\"><a class=\"fusion-read-more\" href=\"https:\/\/bioventrix.com\/2021\/02\/08\/bioventrix-receives-2021-nub-status-1-reimbursement-renewal-in-germany-for-the-revivent-tc-transcatheter-ventricular-enhancement-system\/\" aria-label=\"More on BioVentrix Receives 2021 NUB Status 1 Reimbursement Renewal in Germany for the Revivent TC\u2122 TransCatheter Ventricular Enhancement System\">Read More<\/a><\/div><\/div><\/div><div class=\"fusion-clearfix\"><\/div><\/div>\n<\/article>\n<article id=\"blog-1-post-165\" class=\"fusion-post-grid post-165 post type-post status-publish format-standard hentry category-uncategorized\">\n<div class=\"fusion-post-wrapper\" style=\"background-color:var(--awb-color2);border:1px solid var(--awb-color8);border-bottom-width:3px;\"><div class=\"fusion-post-content-wrapper\" style=\"padding:30px 25px 25px 25px;\"><div class=\"fusion-post-content post-content\"><h2 class=\"blog-shortcode-post-title entry-title\"><a href=\"https:\/\/bioventrix.com\/2021\/01\/06\/bioventrix-announces-jerry-estep-md-as-co-principal-investigator-for-alive-pivotal-trial-studying-a-transcatheter-device-for-heart-failure\/\">BioVentrix Announces Jerry Estep, MD, as Co-Principal Investigator for ALIVE Pivotal Trial Studying a Transcatheter Device for Heart Failure<\/a><\/h2><p class=\"fusion-single-line-meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/bioventrix.com\/author\/michael\/\" title=\"Posts by Michael\" rel=\"author\">Michael<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2022-11-18T20:42:51+00:00<\/span><span>January 6, 2021<\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><div class=\"fusion-content-sep sep-single sep-solid\"><\/div><div class=\"fusion-post-content-container\"><p>SAN RAMON, Calif. \u2013 January 6, 2021 \u2013 BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter Ventricular Restoration (TCVR), today announced that heart failure specialist Jerry Estep, MD, of the Cleveland Clinic has been appointed co-principal investigator of the pivotal ALIVE [...]<\/p><\/div><\/div><div class=\"fusion-meta-info\"><div class=\"fusion-alignleft\"><a class=\"fusion-read-more\" href=\"https:\/\/bioventrix.com\/2021\/01\/06\/bioventrix-announces-jerry-estep-md-as-co-principal-investigator-for-alive-pivotal-trial-studying-a-transcatheter-device-for-heart-failure\/\" aria-label=\"More on BioVentrix Announces Jerry Estep, MD, as Co-Principal Investigator for ALIVE Pivotal Trial Studying a Transcatheter Device for Heart Failure\">Read More<\/a><\/div><\/div><\/div><div class=\"fusion-clearfix\"><\/div><\/div>\n<\/article>\n<article id=\"blog-1-post-168\" class=\"fusion-post-grid post-168 post type-post status-publish format-standard hentry category-uncategorized\">\n<div class=\"fusion-post-wrapper\" style=\"background-color:var(--awb-color2);border:1px solid var(--awb-color8);border-bottom-width:3px;\"><div class=\"fusion-post-content-wrapper\" style=\"padding:30px 25px 25px 25px;\"><div class=\"fusion-post-content post-content\"><h2 class=\"blog-shortcode-post-title entry-title\"><a href=\"https:\/\/bioventrix.com\/2020\/10\/05\/bioventrix-announces-the-appointment-of-cardiac-device-veteran-chris-wolff-as-vice-president-of-u-s-sales\/\">BioVentrix Announces the Appointment of Cardiac Device Veteran Chris Wolff as Vice President of U.S. Sales<\/a><\/h2><p class=\"fusion-single-line-meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/bioventrix.com\/author\/michael\/\" title=\"Posts by Michael\" rel=\"author\">Michael<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2022-11-18T20:45:19+00:00<\/span><span>October 5, 2020<\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><div class=\"fusion-content-sep sep-single sep-solid\"><\/div><div class=\"fusion-post-content-container\"><p>San Ramon, CA, USA \u2013 October 5, 2020 \u2013 BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter Ventricular Restoration (TCVR), today announced that Chris Wolff has been named Vice President of U.S. Sales. In this role, Mr. Wolff will be responsible [...]<\/p><\/div><\/div><div class=\"fusion-meta-info\"><div class=\"fusion-alignleft\"><a class=\"fusion-read-more\" href=\"https:\/\/bioventrix.com\/2020\/10\/05\/bioventrix-announces-the-appointment-of-cardiac-device-veteran-chris-wolff-as-vice-president-of-u-s-sales\/\" aria-label=\"More on BioVentrix Announces the Appointment of Cardiac Device Veteran Chris Wolff as Vice President of U.S. Sales\">Read More<\/a><\/div><\/div><\/div><div class=\"fusion-clearfix\"><\/div><\/div>\n<\/article>\n<article id=\"blog-1-post-778\" class=\"fusion-post-grid post-778 post type-post status-publish format-standard hentry category-uncategorized\">\n<div class=\"fusion-post-wrapper\" style=\"background-color:var(--awb-color2);border:1px solid var(--awb-color8);border-bottom-width:3px;\"><div class=\"fusion-post-content-wrapper\" style=\"padding:30px 25px 25px 25px;\"><div class=\"fusion-post-content post-content\"><h2 class=\"blog-shortcode-post-title entry-title\"><a href=\"https:\/\/bioventrix.com\/2020\/09\/29\/neuartige-herzoperation-in-tubingen-durchgefuhrt\/\">Neuartige Herzoperation in T\u00fcbingen durchgef\u00fchrt<\/a><\/h2><p class=\"fusion-single-line-meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/bioventrix.com\/author\/michael\/\" title=\"Posts by Michael\" rel=\"author\">Michael<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2022-11-26T05:45:58+00:00<\/span><span>September 29, 2020<\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><div class=\"fusion-content-sep sep-single sep-solid\"><\/div><div class=\"fusion-post-content-container\"><p>Das T\u00fcbinger Herzzentrum hat nach einer Corona-bedingten Zwangspause erfolgreich einen Herzschw\u00e4che-Patienten mit einem neuartigen Verfahren behandelt. Dabei wurde die linke Herzkammer verkleinert. Der 60-J\u00e4hrige wurde nach einem Herzinfarkt immer schw\u00e4cher. Zuletzt konnte er nur noch wenige Schritte ohne Pause gehen.Nach der Operation mit der minimalinvasiven Methode gehe es dem Patienten [...]<\/p><\/div><\/div><div class=\"fusion-meta-info\"><div class=\"fusion-alignleft\"><a class=\"fusion-read-more\" href=\"https:\/\/bioventrix.com\/2020\/09\/29\/neuartige-herzoperation-in-tubingen-durchgefuhrt\/\" aria-label=\"More on Neuartige Herzoperation in T\u00fcbingen durchgef\u00fchrt\">Read More<\/a><\/div><\/div><\/div><div class=\"fusion-clearfix\"><\/div><\/div>\n<\/article>\n<article id=\"blog-1-post-784\" class=\"fusion-post-grid post-784 post type-post status-publish format-standard hentry category-uncategorized\">\n<div class=\"fusion-post-wrapper\" style=\"background-color:var(--awb-color2);border:1px solid var(--awb-color8);border-bottom-width:3px;\"><div class=\"fusion-post-content-wrapper\" style=\"padding:30px 25px 25px 25px;\"><div class=\"fusion-post-content post-content\"><h2 class=\"blog-shortcode-post-title entry-title\"><a href=\"https:\/\/bioventrix.com\/2020\/09\/08\/kasuistik-zur-postinfarkt-herzinsuffizienz-publiziert\/\">Kasuistik zur Postinfarkt-Herzinsuffizienz publiziert<\/a><\/h2><p class=\"fusion-single-line-meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/bioventrix.com\/author\/michael\/\" title=\"Posts by Michael\" rel=\"author\">Michael<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2022-11-26T05:52:56+00:00<\/span><span>September 8, 2020<\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><div class=\"fusion-content-sep sep-single sep-solid\"><\/div><div class=\"fusion-post-content-container\"><p>January 27, 2022 Erfolgreiches minimalinvasives Postmyokardinfarkt-Verfahren f\u00fchrt zu einem Anstieg der linksventrikul\u00e4ren Ejektionsfraktion von 20 auf 35%Patienten nach Myokardinfarkt entwickeln trotz leitliniengerechter Herzinsuffizienz-Therapien (GDMT, guideline-directed medical therapy) oft fortschreitende Herzinsuffizienz-Symptome.Nun wurde im European Heart Journal eine Kasuistik publiziert, in der ein Patient mit Postinfarkt-Herzinsuffizienz mit dem Revivent TC\u2122-System behandelt wurde.1Dabei [...]<\/p><\/div><\/div><div class=\"fusion-meta-info\"><div class=\"fusion-alignleft\"><a class=\"fusion-read-more\" href=\"https:\/\/bioventrix.com\/2020\/09\/08\/kasuistik-zur-postinfarkt-herzinsuffizienz-publiziert\/\" aria-label=\"More on Kasuistik zur Postinfarkt-Herzinsuffizienz publiziert\">Read More<\/a><\/div><\/div><\/div><div class=\"fusion-clearfix\"><\/div><\/div>\n<\/article>\n<article id=\"blog-1-post-171\" class=\"fusion-post-grid post-171 post type-post status-publish format-standard hentry category-uncategorized\">\n<div class=\"fusion-post-wrapper\" style=\"background-color:var(--awb-color2);border:1px solid var(--awb-color8);border-bottom-width:3px;\"><div class=\"fusion-post-content-wrapper\" style=\"padding:30px 25px 25px 25px;\"><div class=\"fusion-post-content post-content\"><h2 class=\"blog-shortcode-post-title entry-title\"><a href=\"https:\/\/bioventrix.com\/2020\/09\/02\/bioventrix-announces-pivotal-alive-trial-resumes-with-first-patients-treated-with-live-therapy-since-covid-19-pause\/\">BioVentrix Announces Pivotal ALIVE Trial Resumes with First Patients Treated with LIVE Therapy Since COVID-19 Pause<\/a><\/h2><p class=\"fusion-single-line-meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/bioventrix.com\/author\/michael\/\" title=\"Posts by Michael\" rel=\"author\">Michael<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2022-11-19T01:18:14+00:00<\/span><span>September 2, 2020<\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><div class=\"fusion-content-sep sep-single sep-solid\"><\/div><div class=\"fusion-post-content-container\"><p>San Ramon, Calif. \u2013 September 2, 2020 \u2013 BioVentrix, Inc., developer of the first hybrid transcatheter device for left ventricular remodeling after a heart attack, today announced that the Company has resumed cases in the pivotal ALIVE Trial studying Less Invasive Ventricular Enhancement, or LIVE\u2122 Therapy, using the Revivent TC\u2122 [...]<\/p><\/div><\/div><div class=\"fusion-meta-info\"><div class=\"fusion-alignleft\"><a class=\"fusion-read-more\" href=\"https:\/\/bioventrix.com\/2020\/09\/02\/bioventrix-announces-pivotal-alive-trial-resumes-with-first-patients-treated-with-live-therapy-since-covid-19-pause\/\" aria-label=\"More on BioVentrix Announces Pivotal ALIVE Trial Resumes with First Patients Treated with LIVE Therapy Since COVID-19 Pause\">Read More<\/a><\/div><\/div><\/div><div class=\"fusion-clearfix\"><\/div><\/div>\n<\/article>\n<article id=\"blog-1-post-174\" class=\"fusion-post-grid post-174 post type-post status-publish format-standard hentry category-uncategorized\">\n<div class=\"fusion-post-wrapper\" style=\"background-color:var(--awb-color2);border:1px solid var(--awb-color8);border-bottom-width:3px;\"><div class=\"fusion-post-content-wrapper\" style=\"padding:30px 25px 25px 25px;\"><div class=\"fusion-post-content post-content\"><h2 class=\"blog-shortcode-post-title entry-title\"><a href=\"https:\/\/bioventrix.com\/2020\/08\/19\/bioventrix-announces-appointment-of-accredited-public-company-director-raymond-w-cohen-to-its-board-of-directors\/\">BioVentrix Announces Appointment of Accredited Public Company Director, Raymond W. Cohen, to its Board of Directors<\/a><\/h2><p class=\"fusion-single-line-meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/bioventrix.com\/author\/michael\/\" title=\"Posts by Michael\" rel=\"author\">Michael<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2022-11-19T01:19:49+00:00<\/span><span>August 19, 2020<\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><div class=\"fusion-content-sep sep-single sep-solid\"><\/div><div class=\"fusion-post-content-container\"><p>SAN RAMON, Calif. \u2013 August 12, 2020 \u2013 BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure via Transcatheter Ventricular Restoration (TCVR), today announced the appointment of Raymond W. Cohen to the Company\u2019s board of directors.Mr. Cohen, an accredited public company director, has nearly 40 [...]<\/p><\/div><\/div><div class=\"fusion-meta-info\"><div class=\"fusion-alignleft\"><a class=\"fusion-read-more\" href=\"https:\/\/bioventrix.com\/2020\/08\/19\/bioventrix-announces-appointment-of-accredited-public-company-director-raymond-w-cohen-to-its-board-of-directors\/\" aria-label=\"More on BioVentrix Announces Appointment of Accredited Public Company Director, Raymond W. Cohen, to its Board of Directors\">Read More<\/a><\/div><\/div><\/div><div class=\"fusion-clearfix\"><\/div><\/div>\n<\/article>\n<div class=\"fusion-clearfix\"><\/div><\/div><div class=\"pagination clearfix\"><span class=\"current\">1<\/span><a href=\"https:\/\/bioventrix.com\/wp-json\/wp\/v2\/pages\/180\/page\/2\/\" class=\"inactive\">2<\/a><a class=\"pagination-next\" rel=\"next\" href=\"https:\/\/bioventrix.com\/wp-json\/wp\/v2\/pages\/180\/page\/2\/\"><span class=\"page-text\">Next<\/span><span class=\"page-next\"><\/span><\/a><\/div><div class=\"fusion-clearfix\"><\/div><\/div><\/div><\/div><\/div><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Press Releases - BioVentrix<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bioventrix.com\/press-releases\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Press Releases - BioVentrix\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bioventrix.com\/press-releases\/\" \/>\n<meta property=\"og:site_name\" content=\"BioVentrix\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-16T20:42:31+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@BioVentrix\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bioventrix.com\/press-releases\/\",\"url\":\"https:\/\/bioventrix.com\/press-releases\/\",\"name\":\"Press Releases - BioVentrix\",\"isPartOf\":{\"@id\":\"https:\/\/bioventrix.com\/#website\"},\"datePublished\":\"2022-11-19T01:24:55+00:00\",\"dateModified\":\"2023-04-16T20:42:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/bioventrix.com\/press-releases\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bioventrix.com\/press-releases\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bioventrix.com\/press-releases\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bioventrix.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Press Releases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/bioventrix.com\/#website\",\"url\":\"https:\/\/bioventrix.com\/\",\"name\":\"BioVentrix\",\"description\":\"Less Invasive Ventricular Enhancement\",\"publisher\":{\"@id\":\"https:\/\/bioventrix.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/bioventrix.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/bioventrix.com\/#organization\",\"name\":\"BioVentrix\",\"url\":\"https:\/\/bioventrix.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/bioventrix.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/bioventrix.com\/wp-content\/uploads\/2023\/08\/BioVentrix_logo_50-reg-2.png\",\"contentUrl\":\"https:\/\/bioventrix.com\/wp-content\/uploads\/2023\/08\/BioVentrix_logo_50-reg-2.png\",\"width\":235,\"height\":50,\"caption\":\"BioVentrix\"},\"image\":{\"@id\":\"https:\/\/bioventrix.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/BioVentrix\",\"https:\/\/www.youtube.com\/channel\/UCuRMr53GvBl_8PgS6Rym_SA\",\"https:\/\/www.linkedin.com\/company\/bioventrix\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Press Releases - BioVentrix","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bioventrix.com\/press-releases\/","og_locale":"en_US","og_type":"article","og_title":"Press Releases - BioVentrix","og_url":"https:\/\/bioventrix.com\/press-releases\/","og_site_name":"BioVentrix","article_modified_time":"2023-04-16T20:42:31+00:00","twitter_card":"summary_large_image","twitter_site":"@BioVentrix","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/bioventrix.com\/press-releases\/","url":"https:\/\/bioventrix.com\/press-releases\/","name":"Press Releases - BioVentrix","isPartOf":{"@id":"https:\/\/bioventrix.com\/#website"},"datePublished":"2022-11-19T01:24:55+00:00","dateModified":"2023-04-16T20:42:31+00:00","breadcrumb":{"@id":"https:\/\/bioventrix.com\/press-releases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bioventrix.com\/press-releases\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bioventrix.com\/press-releases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bioventrix.com\/"},{"@type":"ListItem","position":2,"name":"Press Releases"}]},{"@type":"WebSite","@id":"https:\/\/bioventrix.com\/#website","url":"https:\/\/bioventrix.com\/","name":"BioVentrix","description":"Less Invasive Ventricular Enhancement","publisher":{"@id":"https:\/\/bioventrix.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bioventrix.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/bioventrix.com\/#organization","name":"BioVentrix","url":"https:\/\/bioventrix.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/bioventrix.com\/#\/schema\/logo\/image\/","url":"https:\/\/bioventrix.com\/wp-content\/uploads\/2023\/08\/BioVentrix_logo_50-reg-2.png","contentUrl":"https:\/\/bioventrix.com\/wp-content\/uploads\/2023\/08\/BioVentrix_logo_50-reg-2.png","width":235,"height":50,"caption":"BioVentrix"},"image":{"@id":"https:\/\/bioventrix.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/BioVentrix","https:\/\/www.youtube.com\/channel\/UCuRMr53GvBl_8PgS6Rym_SA","https:\/\/www.linkedin.com\/company\/bioventrix\/"]}]}},"_links":{"self":[{"href":"https:\/\/bioventrix.com\/wp-json\/wp\/v2\/pages\/180"}],"collection":[{"href":"https:\/\/bioventrix.com\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/bioventrix.com\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/bioventrix.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bioventrix.com\/wp-json\/wp\/v2\/comments?post=180"}],"version-history":[{"count":4,"href":"https:\/\/bioventrix.com\/wp-json\/wp\/v2\/pages\/180\/revisions"}],"predecessor-version":[{"id":686,"href":"https:\/\/bioventrix.com\/wp-json\/wp\/v2\/pages\/180\/revisions\/686"}],"wp:attachment":[{"href":"https:\/\/bioventrix.com\/wp-json\/wp\/v2\/media?parent=180"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}